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Background: Albuminuria and glomerular ﬁ  ltration rate (GFR), two factors linked to kidney 
and vascular function, may inﬂ  uence longitudinal blood pressure (BP) responses to complex 
antihypertensive drug regimens.
Methods: We reviewed the clinic records of 459 patients with hypertension in an urban, 
academic practice.
Results: Mean patient age was 57-years, 89% of patients were African American, and 69% 
were women. Mean patient systolic/diastolic BP (SBP/DBP) at baseline was 171/98 mmHg 
while taking an average of 3.3 antihypertensive medications. At baseline, 27% of patients had 
estimated (e)GFR  60 ml/min/1.732, 28% had micro-albuminuria (30–300 mg/g) and 16% had 
macro-albuminuria ( 300 mg/g). The average longitudinal BP decline over the observation 
period (mean 7.2 visits) was 25/12 mmHg. In adjusted regression models, macro-albuminuria 
predicted a 10.3 mmHg lesser longitudinal SBP reduction (p   0.001) and a 7.9 mmHg lesser 
longitudinal DBP reduction (p   0.001); similarly eGFR  60 ml/min/1.732 predicted an 8.4 
mmHg lesser longitudinal SBP reduction (p   0.001) and a 4.5 lesser longitudinal DBP reduction 
(p   0.001). Presence of either micro- or macro-albuminuria, or lower eGFR, also signiﬁ  cantly 
delayed the time to attainment of goal BP.
Conclusions: These data suggest that an attenuated decline in BP in drug-treated hyperten-
sives, resulting in higher average BP levels over the long-term, may mediate a portion of the 
increased risk of cardiovascular-renal disease linked to elevated urinary albumin excretion and 
reduced eGFR.
Keywords: albuminuria, glomerular ﬁ  ltration rate, blood pressure, antihypertensive drug 
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Introduction
Level of kidney function may inﬂ  uence blood pressure (BP) responses to antihy-
pertensive drug therapies given that diminished glomerular ﬁ  ltration predisposes to 
sodium retention unless dietary sodium intake is restricted. Moreover, vasodilator 
drugs – especially those that increase the capacitance of venous vessels (Abshagen 
and von Mollendorff 1986; Taylor 1988) – can promote salt and water retention, 
which may attenuate BP reductions with these agents when dietary sodium intake 
is ad lib (Weir et al 1997, 1998). Elevated urinary albumin excretion, even amongst 
normotensives, has been linked to attenuated endothelial and non-endothelial mediated 
arterial dilatory capacity (Clausen et al 2001). Other studies have linked increased 
urinary albumin excretion to endothelial dysfunction (Pedrinelli et al 1994), more 
rapid loss of kidney function (Bianchi et al 1997, 1999; Pinto-Sietsma et al 2000; 
Campbell et al 2003), increased left ventricular mass and cardiac structural changes 
(Leoncini et al 2002; Plavnik et al 2002), sodium sensitivity (Imanishi et al 2001; 
Cubeddu et al 2003) and increased global cardiovascular risk (Pedrinelli et al 2002). Vascular Health and Risk Management 2007:3(6) 1030
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Patients with microalbuminuria have been observed to have 
higher systolic, diastolic, and mean arterial BP compared to 
patients without microalbuminuria (Cruz et al 1997).
Thus, we sought to examine whether albuminuria and 
estimated glomerular ﬁ  ltration rate (eGFR) attenuate the 
longitudinal BP response to complex antihypertensive drug 
regimens. We hypothesized that albuminuria might represent 
a state of diminished vascular response to vasculoactive 
drugs and would therefore blunt longitudinal BP responses 
to complex antihypertensive drug regimens. Conversely, we 
postulated that eGFR would directly correlate with longitudi-
nal BP reductions. If our hypotheses were correct, then higher 
BP levels over the long-term would be at least one mechanism 
through which albuminuria and/or reduced eGFR contribute 
to the heightened cardiovascular-renal risks associated with 
reductions in kidney function and/or albuminuria.
Methods
The research design was an observational study of hyper-
tensive patients in an urban academic hypertension clinic 
in the Department of Internal Medicine, at Wayne State 
University, Detroit Michigan. Patients with a baseline 
evaluation and at least one post-baseline clinic visit, who 
satisﬁ  ed co-morbidity speciﬁ  c BP criteria for the diagnosis 
of hypertension according to published guidelines from 
the Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC) 
(JNC VI 1997; JNC VII 2003), who had baseline data on 
albuminuria and eGFR status, and who were not at JNC 
goal BP at baseline were included. Data collected during 
clinic visits occurring from January 2001 through mid-
May 2006 were considered. Antihypertensive therapy and 
lifestyle interventions were prescribed in accordance with 
routine clinical practice as guided by either JNC-VI (prior 
to mid-August 2003) or JNC-VII (from mid-August 2003) 
target BP goals depending on the time frame of observa-
tion (JNC VI 1997; JNC VII 2003). Patient demographic, 
clinical (including medication), and laboratory data were 
collected and maintained using an Institutional Review 
Board approved electronic medical record/clinical decision 
support system – MedTrace (MedTrace Inc., Orchard Lake, 
MI, USA). Data were stripped of individual patient identi-
ﬁ  ers and imported into a research database for analysis. 
This project was reviewed and approved by the Wayne State 
University, Institutional Review Board.
Patients were characterized by age, gender, and race 
(African American, non-African American). Diabetes was 
deﬁ  ned based on use of insulin and/or oral hypoglycemic 
agents or elevated glucose levels (fasting glucose   126 mg/dL 
or random glucose   200 mg/dL). Obesity status was deter-
mined from calculation of body mass index (BMI) [weight 
(Kg)/ height (m2)], with obesity deﬁ  ned as BMI   30.0 kg/m2. 
Anti-hypertensive therapeutic intensity scores (daily dose 
divided by maximum FDA approved dose, summed across 
medication class) were calculated from visit-specific 
prescribed therapeutic choices. The Modified Diet and 
Renal Disease (MDRD) formula ([eGFR] = 186.3*[serum 
creatinine–1.154]*[age–0.203]*0.742 for women; *1.21 for African 
Americans) (Levy et al 1999) was used to calculate eGFR at 
baseline. eGFR values  60 ml/min/1.73m2 (Kidney Disease 
Outcomes Quality Initiative [K/DOQI] categories 3–5) were 
considered abnormal, and indicated at least moderately 
reduced kidney function (NKF 2002). Albuminuria status at 
baseline was determined from random spot urine albumin:
creatinine ratio measurements and categorized as normal 
( 30 mg/g), microalbuminuria (30–300 mg/g), or macroal-
buminuria ( 300 mg/g) (Keane and Eknoyan 1999).
Longitudinal BP response was defined as baseline 
systolic (SBP) or diastolic blood pressure (DBP) minus 
visit-specific SBP or DBP, respectively, and calculated 
at all post-baseline visits. In addition, patients attaining 
co-morbidity specific (JNC VI or JNC VII) goal BP 
levels at least once during follow-up were identiﬁ  ed. The 
BP goal for patients with proteinuria  1 gram/24 hours was 
 125/75 mmHg using JNC VI criteria and  130/80 mmHg 
using JNC VII criteria; the BP goal for patients with diabetes 
mellitus, heart failure, and/or renal insufficiency was 
 130/85 mmHg using JNC VI criteria and  130/80 mmHg 
using JNC VII criteria (except heart failure); the BP goal for 
all others was  140/90 mmHg using either criteria. Differ-
ences from BP goal at baseline were calculated as baseline 
SBP or DBP minus goal SBP or DBP, respectively.
Statistical analysis
Statistical analyses were performed using SAS statistical 
software (SAS, version 9.1, SAS Institute, Cary, NC). Popu-
lation characteristics, including demographics, BP response, 
and attainment of BP goal, were evaluated by eGFR and 
albuminuria cut-points using chi-square statistics for cat-
egorical variables and Wilcoxon rank sum tests and ANOVA 
techniques for continuous values. Repeated measures linear 
mixed effects regression models, with appropriate correla-
tion structures to account for within-subject correlation 
across multiple observations on individual patients, were 
used to examine the inﬂ  uence of eGFR and albuminuria 
categories on visit-speciﬁ  c SBP and DBP response; models Vascular Health and Risk Management 2007:3(6) 1031
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were adjusted for patient demographics (age, gender, race), 
diabetes and obesity status, difference between baseline BP 
and goal BP, and visit-speciﬁ  c anti-hypertensive therapeutic 
intensity scores. Time to BP goal attainment was evaluated 
using survival analysis with comparison of hazard curves 
stratiﬁ  ed by eGFR and albuminuria categories; similarly, 
factors associated with goal attainment with calculation 
of hazard ratios were determined using Cox proportional 
hazards models.
Results
Data were available on 459 patients meeting the inclusion cri-
teria, including 437 patients who were not at systolic BP goal 
and 365 patients who were not at diastolic goal. The average 
age of participants was 57-years (range 19–88-years); 89% 
(n = 408) of the study population was African American 
and 69% (n = 315) were women. Thirty-four percent 
(n = 157) of patients had diabetes, and 59% (n = 262) were 
obese (BMI   30.0 kg/m2). Mean baseline SBP/DBP was 
171/98 mmHg; mean SBP/DBP difference from goal BP at 
baseline was 39/18 mmHg. Participating patients were taking 
an average of 3.3 (range 0–7) antihypertensive medications 
at baseline, and had a mean baseline anti-hypertensive thera-
peutic intensity score of 2.0 (range 0–11.8). Mean baseline 
eGFR was 75 ml/min/1.732 (range 14–23) and 27% (n = 125) 
of the population had eGFR values  60 ml/min/1.732. Mean 
baseline urine albumin:creatinine ratio was 254 mg/g (range 
0–10,333) and 43% (n = 198) of patients had either micro- or 
macro-albuminuria.
During the study period, patients had an average of 
7.2 clinic visits (range 2–44) over a mean of 16.8-months 
(range 0.23–56). During follow-up patients were prescribed 
an average of 3.4 (range 0–7) antihypertensive medications 
with a mean anti-hypertensive therapeutic intensity score of 
2.2 (range 0–10.7). The mean longitudinal decline in SBP 
during follow-up was 25.4 mmHg (SD = 24.6) and the mean 
longitudinal decline in DBP was 12.2 mmHg (SD = 12.7). 
Fifty-ﬁ  ve percent (n = 252) of patients attained both systolic 
and diastolic BP goals during follow-up; mean follow-up 
time to goal attainment was 4.4 visits over an average of 
7.0-months.
In Table 1, patient baseline characteristics and BP 
responses were examined by albuminuria status. Likeli-
hood of micro- or macro-albuminuria signiﬁ  cantly varied 
by age and race, but not by gender or obesity status. As 
expected, albuminuria was more prevalent in patients with 
diabetes and those with lower eGFR values. Mean baseline 
SBP (but not mean baseline DBP) and mean levels above 
systolic and diastolic JNC BP goals were progressively 
greater (versus hypertensives without albuminuria) in those 
with micro- and macro-albuminuria; however, unadjusted 
mean post-baseline systolic and diastolic BP responses did 
not signiﬁ  cantly vary by albuminuria status. Patients with 
albuminuria were signiﬁ  cantly less likely than those without 
albuminuria to attain JNC BP goals. At baseline, therapeutic 
intensity scores and number of antihypertensive medications 
at baseline signiﬁ  cantly differed by albuminuria status; both 
were higher among patients with albuminuria compared to 
those without albuminuria.
Patients with eGFR  60 ml/min/1.732 were older, and 
were more likely to have diabetes and either micro- or 
macro-albuminuria than those with higher eGFR values, 
but were equally likely to be male, African American or 
obese (Table 2). In these unadjusted analyses, patients with 
eGFR  60 ml/min/1.732 had reduced post-baseline systolic 
and diastolic BP responses compared to those with higher 
eGFR values, and were signiﬁ  cantly less likely to attain 
JNC BP goals. At baseline, therapeutic intensity scores and 
number of antihypertensive medications at baseline sig-
niﬁ  cantly differed by eGFR status; both were higher among 
patients with reduced eGFR.
Table 3 presents results from two repeated measures linear 
regression models examining the inﬂ  uence of albuminuria and 
eGFR on visit-speciﬁ  c SBP and DBP responses during post-
baseline visits. Macro-albuminuria predicted a 10.3 mmHg 
lesser longitudinal SBP reduction (95% CI = –15.3, –5.4 
p   0.001) and micro-albuminuria predicted a 5.1 mmHg 
lesser reduction (95% CI = –8.6, –1.6, p = 0.005); similarly, 
macro-albuminuria predicted a 7.9 mmHg lesser longitudi-
nal DBP reduction (95% CI = –11.1, –4.6, p   0.001) and 
micro-albuminuria predicted a 3.9 mmHg lesser reduction 
(95% CI = –6.2, –1.6, p = 0.001). Lower eGFR also had a 
signiﬁ  cant impact on reducing longitudinal BP response; 
eGFR  60 ml/min/1.73 m2 predicted an 8.4 mmHg lesser 
longitudinal SBP reduction (95% CI = –12.6, –4.3, p   0.001) 
and a 4.5 mmHg lesser longitudinal DBP reduction (95% 
CI = –7.1, –1.8, p   0.001). These models were adjusted for 
patient characteristics and anti-hypertensive therapeutic inten-
sity; in both models higher therapeutic intensity was signiﬁ  -
cantly associated with greater reduction in longitudinal BP.
Table 4 presents results from two proportional hazards 
models examining the inﬂ  uence of albuminuria and eGFR 
on likelihood of attaining systolic and diastolic BP goals 
during follow-up. Patients with micro- (HR = 0.71, 95% 
CI = 0.53–0.97, p =0.032) or macro-albuminuria (HR = 0.54, 
95% CI = 0.35–0.83, p = 0.005) were signiﬁ  cantly less likely Vascular Health and Risk Management 2007:3(6) 1032
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than patients without albuminuria to attain their systolic 
BP goal; patients with eGFR  60 ml/min/1.73 m2 were 
also less likely to attain systolic BP goals but not signiﬁ  -
cantly. In contrast, neither reduced eGFR nor the presence 
of either micro- or macro-albuminuria were signiﬁ  cantly 
associated with likelihood of attaining diastolic BP goal. 
Higher therapeutic intensity was not signiﬁ  cantly associ-
ated with increased likelihood of either systolic or diastolic 
goal attainment. In fact, mean therapeutic intensity scores 
(2.3 vs 2.6, p = 0.001) and mean number of antihypertensive 
medications (3.4 vs 3.9, p   0.001) were both signiﬁ  cantly 
lower for patients who attained SBP goal (calculated at the 
time of goal attainment) compared to those patients who 
never reached SBP goal (calculated at last follow-up visit). 
Similarly, therapeutic intensity (2.2 vs 2.4, p = 0.06) and 
number of medications (3.3 vs 3.6, p = 0.015) were lower 
for patients attaining DBP goal.
Results from analyses of time-to-attainment of JNC BP 
goal stratiﬁ  ed by albuminuria categories (Figure 1) indicated 
signiﬁ  cant (Log-rank test p   0.001) variation, with a signiﬁ  -
cantly longer time to BP goal attainment for hypertensives 
with micro-albuminuria (median time 12.9-months [95% 
CI = 10.3 to 17.5]) or macro-albuminuria (median time 
24.6-months [95% CI = 9.6 to inﬁ  nity]) compared with those 
without albuminuria (median time 4.9-months [95% CI = 3.6 
to 7.6]). Similarly, time-to-attainment of BP goal stratiﬁ  ed by 
eGFR status (Figure 2) indicated signiﬁ  cantly (Log-rank test 
p = 0.012) greater time to goal attainment for patients with 
eGFR  60 ml/min/1.732 (median time 12.9-months [95% 
CI = 9.1 to 18.4]) compared with those with values  60 ml/
min/1.732 (median time 7.6-months [95% CI = 5.1 to 10.3]).
Discussion
We examined the inﬂ  uence of albuminuria and eGFR on 
longitudinal BP responses to antihypertensive therapy using 
data derived from a population of mostly African American 
patients with hypertension who were managed in an urban 
academic hypertension clinic. Our results demonstrated that 
the presence of micro- or macro-albuminuria was linked to 
an attenuation of the longitudinal BP response to complex 
antihypertensive drug regimens. In our analysis, the impact 
of albuminuria on longitudinal responses and attainment of 
JNC goal BP levels was independent of the level of kidney 
function (eGFR). Albuminuria resulted in a signiﬁ  cantly 
lower proportion of hypertensive patients attaining JNC goal 
BP levels and also prolonged the time to attainment of goal 
Table 1 Characteristics of 459 patients with hypertension, who were not at goal blood pressure (either or both of systolic or 
diastolic BP) at baseline, stratiﬁ  ed by albuminuria status
Characteristic Normal  Albuminuria  Status*    p-value
 (n = 261) Micro-  Macro- 
   albuminuria  albuminuria 
   (n = 126) (n = 72) 
Mean age (SD)  55.4 (12.9)  57.4 (13.1)  59.7 (13.8)  0.046
African American race, n (%)  225 (86.2)  113 (89.7)  70 (97.2)  0.030
Male gender, n (%)  72 (27.6)  43 (34.1)  29 (40.3)  0.09
BMI   30 kg/m2, n (%)  140 (55.8)  79 (63.7)  43 (60.6)  0.32
Diabetes, n (%)  54 (20.7)  58 (46.0)  45 (62.5)   0.001
Mean baseline therapeutic intensity  1.8 (1.1)  2.3 (1.3)  2.3 (1.0)   0.0001
score (SD)       
Mean baseline number of antihypertensive  3.0 (1.4)  3.5 (1.3)  3.8 (1.1)   0.0001
medications (SD)       
Mean baseline SBP, mmHg (SD)  164.9 (22.8)  178.0 (28.5)  181.0 (27.7)   0.001
Mean difference from SBP goal (SD)  31.4 (22.3)  45.7 (27.6)  50.8 (27.8)   0.001
Mean baseline DBP, mmHg (SD)  96.9 (15.0)  100.7 (17.3)  96.7 (20.9)  0.053
Mean difference from DBP goal (SD)  14.4 (11.8)  20.2 (14.0)  24.1 (17.5)   0.001
Mean eGFR [ml/min/1.73 m2] (SD)  80.9 (23.6)  72.7 (24.4)  54.1 (20.3)   0.001
eGFR   60 ml/min/1.73 m2, n (%)  46 (17.6)  38 (30.2)  41 (56.9)   0.001
Mean post-baseline SBP response (SD)  26.6 (21.4)  27.8 (28.2)  24.7 (26.7)  0.80
Mean post-baseline DBP response (SD)  14.3 (11.5)  15.0 (13.1)  15.8 (13.7)  0.50
Attained S/DBP Goal, n (%)  168 (64.4)  59 (46.8)  25 (34.7)   0.001
Note: *Normal =  30 mg/g creatinine; micro-albuminuria = 30–300 mg/g creatinine; macro-albuminuria =  300 mg/g creatinine.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular ﬁ  ltration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; Goal BP, comorbidity-
speciﬁ  c goal blood pressure as deﬁ  ned by JNC-VII guidelines.Vascular Health and Risk Management 2007:3(6) 1033
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BP. Similarly, lower eGFR values ( 60 ml/min/1.732) were 
also linked to attenuation of longitudinal BP response to anti-
hypertensive therapy and with increased time to attainment 
of JNC goal BP levels. Typically, patients with the highest 
baseline BP levels, experience the greatest reductions in BP 
over time (MacFayden et al 1991; Mokwe et al 2004), an 
observation attributable in part to regression to the mean. 
However, we observed a lesser, rather than a greater decline 
in BP in hypertensive patients with albuminuria or low eGFR 
values, lending credence to our thesis that albuminuria and 
Table 2 Characteristics of 459 patients with hypertension, who were not at goal blood pressure (either or both of systolic or 
diastolic BP) at baseline, stratiﬁ  ed by eGFR status
Characteristic eGFR    60 eGFR    60   p-value
   ml/min/1.73  m2   ml/min/1.73 m2 
   (n = 125) (n = 334) 
Mean age (SD)  62.7 (12.2)  54.4 (12.8)   0.001
African American race, N (%)  112 (89.6)  296 (88.6)  0.77
Male gender, n (%)  40 (32.0)  104 (31.1)  0.86
BMI   30 kg/m2, n (%)  68 (55.3)  194 (60.1)  0.36
Diabetes, n (%)  55 (44.0)  102 (30.5)  0.007
Mean baseline therapeutic intensity score (SD)  2.4 (1.4)  1.9 (1.1)   0.0001
Mean baseline number of antihypertensive medications (SD)  3.7 (1.2)  3.1 (1.4)   0.0001
Mean baseline SBP, mmHg (SD)  173.7 (27.2)  170.0 (25.8)  0.14
Mean difference from SBP goal (SD)  45.5 (25.9)  36.1 (25.7)   0.001
Mean baseline DBP, mmHg (SD)  93.4 (17.2)  99.6 (16.2)   0.001
Mean difference from DBP goal (SD)  18.4 (14.6)  17.2 (13.6)  0.57
Mean urine albumin: creatinine mg/g (SD)  663.1 (1439.7)  100.2 (273.0)   0.001
Albuminuria status*       0.001
 Normal  46  (36.8)  215  (64.4) 
  Micro-albuminuria  38 (30.4)  88 (26.4) 
  Macro-albuminuria  41 (32.8)  31 (9.3) 
Mean post-baseline SBP response (SD)  22.6 (23.5)  28.1 (24.5)  0.06
Mean post-baseline DBP response (SD)  12.2 (11.6)  15.5 (12.4)  0.040
Attained BP Goal, N (%)  58 (46.4)  194 (58.1)  0.025
Note: *Normal =  30 mg/g creatinine; micro-albuminuria = 30–300 mg/g creatinine; macro-albuminuria =  300 mg/g creatinine.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular ﬁ  ltration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; Goal BP, comorbidity-
speciﬁ  c goal blood pressure as deﬁ  ned by JNC-VII guidelines. 
Table 3 Results from two repeated measures linear mixed effects regression models examining the inﬂ  uence of eGFR and albumin-
uria on systolic and diastolic blood pressure (BP) response*
Covariate  Systolic blood pressure response    Diastolic blood pressure response
    Estimate^ 95%  CI  p-value Estimate^ 95%  CI  p-value
Age (years)  −0.28  −0.43, −0.13   0.001 0.08  −0.01, 0.17  0.11
Male gender  −1.14  −5.04, 2.76  0.57  −0.38  −2.36, 1.94  0.75
African American race  −5.11  −11.33, 1.11  0.11  −2.83  −6.75, 1.09  0.16
Diabetes   −5.68  −9.55, −1.81 0.004  −0.89  −3.31, 1.53  0.47
BMI   30 kg/m2  −3.71  −7.00, −0.42 0.027  −1.48  −3.58, 0.62  0.17
Difference from SBP or  0.68  0.61, 0.75   0.001 0.51  0.43,  0.59   0.001
DBP goal at baseline         
Therapeutic intensity score# 2.09  0.95,  3.23   0.001 1.27  0.50,  1.34  0.001
eGFR   60 ml/min/1.73 m2  −8.44  −12.63, −4.25   0.001  −4.48  −7.12, −1.84   0.001
Albuminuria status†:         
 Macro-albuminuria  −10.32  −15.28, −5.36   0.001  −7.88  −11.14, −4.62   0.001
 Micro-albuminuria  −5.08  −8.63, −1.55 0.005  −3.88  −6.18, −1.58 0.001
Note: * Visit-speciﬁ  c change in BP from baseline (baseline BP minus visit-speciﬁ  c BP calculated at each post-baseline visit).
† With normal albumin as reference. Normal =  30 mg/g creatinine; micro-albuminuria = 30–300 mg/g creatinine; macro-albuminuria =  300 mg/g creatinine.
# Visit-speciﬁ  c anti-hypertension therapeutic intensity score: calculated as daily dose/maximum FDA approved dose, summed across medication class.
^Estimate (beta coefﬁ  cient) deviation from expected (mean [intercept]) BP response in mmHg for participants with this characteristic compared to those without, given 
inclusion of all other variables in adjusted model. Positive values indicate greater reductions in BP. 
Abbreviations: eGFR, estimated glomerular ﬁ  ltration rate; BMI, body mass index; BP, blood pressure.Vascular Health and Risk Management 2007:3(6) 1034
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reduced eGFR confer true resistance to antihypertensive 
drug therapy.
Microalbuminuria has been linked to glomerular hyper-
ﬁ  ltration, increased glomerular permeability and increased 
intraglomerular pressure (Keane and Eknoyan 1999). Glo-
merular injury, almost irrespective of etiology, typically 
leads to a rise in systemic BP. Thus, an association between 
albuminuria and elevated BP is not surprising (Gosling and 
Beevers 1989; Jensen et al 1995; Cruz et al 1997). Albumin-
uria appears to be a marker for global vascular dysfunction 
extending beyond the kidney. There is clear evidence that 
albuminuria is linked to endothelial and non-endothelial 
arterial dilatory capacity (Pedrinelli et al 1994; Clausen 
et al 2001). The level of circulating von Willebrand factor, 
a marker of vascular endothelial damage and predictor of 
cardiovascular events, is elevated in hypertensive patients 
with micro-albuminuria (Pedrinelli et al 1994).
On the arterial side, vascular dysfunction might lead to 
vasoconstriction and diminished responsiveness to vasculo-
active antihypertensive agents and therefore lesser reductions 
in BP over the long-term relative to drug-treated hyperten-
sives without albuminuria. On the venous side of the vascular 
system, which contains 75%–80% of the blood volume, 
endothelial dysfunction has been linked to reduced venous 
capacitance and centralization of the blood volume (Francis 
and Cohn 1990; Abrams 1996). Patients with albuminuria are 
more salt-sensitive than non-albuminuric patients (Campese 
1994; Nesovic et al 1996). Salt sensitivity has, in turn, been 
linked with higher antihypertensive medication requirements 
in drug-treated hypertensives (Hooper et al 2004). Thus, it 
is plausible to speculate that some of the resistance to drug 
therapy we observed in our hypertensive patients may have 
been explained by enhanced renal absorption of sodium. 
Renal tubular binding of diuretics to ﬁ  ltered proteins is 
another possible mechanism of resistance to antihyperten-
sive drug therapy in patients with albuminuria. Accordingly, 
proteinuria has also been shown to result in decreased levels 
of diuretic drugs reaching their respective active sites within 
the renal tubules (Kirchner et al 1992). Nevertheless, we were 
unable to directly test mechanistic explanations; therefore 
we can only speculate about the mechanisms of resistance to 
therapies in hypertensive patients with albuminuria.
There are several important considerations when inter-
preting our study results. First, our study was observational 
and therefore subject to biases that are inherent in non-
randomized study designs. An important limitation of our 
study is that our referral cohort of hypertensive patients had 
higher BP levels at baseline, was more intensively treated 
than the majority of drug-treated hypertensives, and was 
disproportionately African American women. The fact that 
we classiﬁ  ed eGFR and albuminuria status on the basis of 
single serum creatinine and urinary albumin:creatinine ratio 
determinations, respectively, likely caused misclassiﬁ  cation 
of these covariates across time. However, this would have 
lessened rather than increased the probability of positive 
ﬁ  ndings when longitudinal BP response data were contrasted 
across albuminuria categories. Another potential weakness in 
our analysis is that we did not adjust for the effect of speciﬁ  c 
anti-hypertensive therapies. Patients like those studied here 
typically require, and are very likely already taking, multiple 
Table 4 Results from two proportional hazards models examining the inﬂ  uence of eGFR and albuminuria status, on likelihood of 
attaining systolic and diastolic blood pressure goals during follow-up
Covariate  Attainment of SBP goal    Attainment of DBP goal
    Hazard ratio  95% CI  p-value  Hazard ratio  95% CI  p-value
Age (years)  0.99  0.98–1.00  0.17  1.00  0.99–1.01  0.64
Male gender  0.71  0.54–0.95  0.020  0.77  0.58–1.03  0.07
African American race  1.02  0.67–1.55  0.91  1.06  0.69–1.63  0.80
Diabetes   0.83  0.62–1.12  0.23  1.31  0.96–1.78  0.09
BMI   30 kg/m2 0.76  0.58–1.00  0.048  0.67  0.50–0.90  0.008
Therapeutic intensity score# 1.00  0.90–1.12  0.98  1.02  0.91–1.14  0.75
Difference from SBP or DBP   0.99  0.98–0.99   0.001 0.97  0.96–0.98  0.001
goal at baseline            
eGFR  60 ml/min/1.73 m2 0.74  0.54–1.02  0.07  0.85  0.61–1.18  0.32
Albuminuria status*:           
 Macro-albuminuria  0.54  0.35–0.83  0.005  0.87  0.56–1.36  0.54
 Micro-albuminuria  0.71  0.53–0.97  0.032  0.82  0.60–1.13  0.23
Note: Model adjusted for visit month (time).
*With normal albumin as reference. Normal =  30 mg/g creatinine; micro-albuminuria = 30–300 mg/g creatinine; macro-albuminuria =  300 mg/g creatinine.
#Anti-hypertension therapeutic intensity score: calculated as daily dose/maximum FDA approved dose, summed across medication class.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.Vascular Health and Risk Management 2007:3(6) 1035
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Figure 1 Time to attainment of systolic and diastolic blood pressure goal (JNC-VII guidelines) by albuminuria status.
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antihypertensive drug therapies, initiated and subsequently 
changed based on clinician decisions rather than in a sys-
tematic fashion. In order to adjust multivariate models for 
the effect of anti-hypertensive medication use on blood pres-
sure response, we calculated visit-speciﬁ  c anti-hypertensive 
therapeutic intensity scores (daily dose divided by maximum 
FDA approved dose, summed across medication class); in 
both models examining longitudinal blood pressure response, 
higher therapeutic intensity was signiﬁ  cantly associated with 
greater reduction in longitudinal BP.
We believe that our observations are potentially important 
for several reasons. Measurement of urine albumin excre-
tion is readily available to clinicians (and is speciﬁ  cally 
recommended for measurement in all hypertensive patients 
for risk stratiﬁ  cation in the JNC VII report) from random 
spot urine samples that are reasonably well correlated with 
estimates obtained from 24-hour collections (Ng et al 2000; 
Claudi and Cooper 2001); similarly eGFR can be calculated 
from serum creatinine values (Levey et al 1999). Second, 
though the mechanisms through which albuminuria increases 
cardiovascular-renal risk are only partially understood 
(Raynaud et al 1998), our data suggest that a well established 
and modiﬁ  able risk factor, BP elevations, may explain part 
of the risk imparted by albuminuria. Though other studies 
have shown higher levels of BP in patients with albumin-
uria/proteinuria, they have not reported the inﬂ  uence of 
albuminuria on longitudinal BP responses (Hunsicker et al 
1997; Agodoa et al 2001). The commingling of albuminuria 
with BP complicates the interpretation of clinical studies that 
report endpoints according to albuminuria status, unless this 
fact is taken into account in the design and/or analysis of the 
data. It is our hope that this report will stimulate reanalysis 
of the inﬂ  uence of higher levels of BP on the risk that has 
been attributed to albuminuria, per se.
In summary, the presence of albuminuria and reduced 
eGFR appears to identify patients who will manifest attenu-
ated responses to antihypertensive pharmacotherapy. BP 
elevations over the long-term may be one mechanism through 
which albuminuria and reduced eGFR mediate an increased 
risk of cardiovascular-renal disease among patients receiving 
various complex antihypertensive regimens. Our ﬁ  ndings 
need to be conﬁ  rmed in other longitudinal clinical data sets.
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